NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

糖尿病性末梢神經病變(DPN)-流行病學預測-2030

Diabetic Peripheral Neuropathy - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 923584
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
糖尿病性末梢神經病變(DPN)-流行病學預測-2030 Diabetic Peripheral Neuropathy - Epidemiology Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

主要7個國家 (美國、德國、西班牙、義大利、法國、英國、日本)的糖尿病性末梢神經病變 (DPN) 市場在2017年達到了3,904,730病例數。

本報告提供全球糖尿病性末梢神經病變 (DPN) 治療藥市場相關調查分析,疾病的背景,流行病學,主要7個國家的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 摘要整理

第3章 糖尿病性末梢神經病變 (DPN) :患者概要

  • 2017年:DPN的總患者佔有率 (%) 分佈
  • 2030年:DPN的總患者佔有率 (%) 分佈

第4章 流行病學方法

第5章 疾病的背景和概要:糖尿病性末梢神經病變 (DPN)

  • 簡介
  • 糖尿病神經病變的分類
  • 症狀
  • 危險因素
  • 病因
  • 診斷
  • POCD的DPN的早期診斷的最近的發展
  • 鑑別診斷

第6章 流行病學和患者族群:糖尿病性末梢神經病變 (DPN)

  • 主要調查結果
  • 主要7個國家的糖尿病性末梢神經病變 (DPN) 和確診的總患者數
  • 美國
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國 (UK)
  • 日本

第7章 DPN的治療和管理

  • DPN管理的指南

第8章 未滿足需求

第9章 參考文獻

第10章 附錄

第11章 調查方法

第12章 DelveInsight的功能

第13章 免責事項

第14章 關於DelveInsight

目錄
Product Code: DIEI0899

DelveInsight's 'Diabetic Peripheral Neuropathy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Peripheral Neuropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Diabetic Peripheral Neuropathy Understanding

The DelveInsight Diabetic Peripheral Neuropathy epidemiology report gives a thorough understanding of the Diabetic Peripheral Neuropathy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Diabetic Peripheral Neuropathy in the US, Europe, and Japan. The report covers the detailed information of the Diabetic Peripheral Neuropathy epidemiology scenario in seven major countries (US, EU5, and Japan).

Diabetic Peripheral Neuropathy Epidemiology Perspective by DelveInsight

The Diabetic Peripheral Neuropathy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Diabetic Peripheral Neuropathy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Diabetic Peripheral Neuropathy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Diabetic Peripheral Neuropathy Detailed Epidemiology Segmentation

The Diabetic Peripheral Neuropathy epidemiology covered in the report provides historical as well as forecasted Diabetic Peripheral Neuropathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Diabetic Peripheral Neuropathy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Diabetic Peripheral Neuropathy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Diabetic Peripheral Neuropathy Epidemiology Report and Model provide an overview of the risk factors and global trends of Diabetic Peripheral Neuropathy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Diabetic Peripheral Neuropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Diabetic Peripheral Neuropathy
  • The report provides the segmentation of the Diabetic Peripheral Neuropathy epidemiology

Report Highlights

  • 11-Year Forecast of Diabetic Peripheral Neuropathy epidemiology
  • 7MM Coverage
  • Total Cases of Diabetic Peripheral Neuropathy
  • Total Cases of Diabetic Peripheral Neuropathy according to segmentation
  • Diagnosed cases of Diabetic Peripheral Neuropathy

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diabetic Peripheral Neuropathy?
  • What are the key findings pertaining to the Diabetic Peripheral Neuropathy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Diabetic Peripheral Neuropathy across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Diabetic Peripheral Neuropathy?
  • What are the currently available treatments of Diabetic Peripheral Neuropathy?

Reasons to buy

  • The Diabetic Peripheral Neuropathy Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Diabetic Peripheral Neuropathy market
  • Quantify patient populations in the global Diabetic Peripheral Neuropathy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Diabetic Peripheral Neuropathy therapeutics in each of the markets covered
  • Understand the magnitude of Diabetic Peripheral Neuropathy population by its epidemiology
  • The Diabetic Peripheral Neuropathy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Diabetic Peripheral Neuropathy

3. Diabetic Peripheral Neuropathy: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Diabetic Peripheral Neuropathy Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Diabetic Peripheral Neuropathy Treatment and Management
  • 6.2. Diabetic Peripheral Neuropathy Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1 Diabetic Peripheral Neuropathy Epidemiology in 7MM (2017-2030)
  • Table 2 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3 Diabetic Peripheral Neuropathy Epidemiology in the United States (2017-2030)
  • Table 4 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 Diabetic Peripheral Neuropathy Epidemiology in Germany (2017-2030)
  • Table 6 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 Diabetic Peripheral Neuropathy Epidemiology in France (2017-2030)
  • Table 8 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 Diabetic Peripheral Neuropathy Epidemiology in Italy (2017-2030)
  • Table 10 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 Diabetic Peripheral Neuropathy Epidemiology in Spain (2017-2030)
  • Table 12 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 Diabetic Peripheral Neuropathy Epidemiology in the United Kingdom (2017-2030)
  • Table 14 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15 Diabetic Peripheral Neuropathy Epidemiology in Japan (2017-2030)
  • Table 16 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1 Diabetic Peripheral Neuropathy Epidemiology in 7MM (2017-2030)
  • Figure 2 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3 Diabetic Peripheral Neuropathy Epidemiology in the United States (2017-2030)
  • Figure 4 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 Diabetic Peripheral Neuropathy Epidemiology in Germany (2017-2030)
  • Figure 6 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 Diabetic Peripheral Neuropathy Epidemiology in France (2017-2030)
  • Figure 8 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 Diabetic Peripheral Neuropathy Epidemiology in Italy (2017-2030)
  • Figure 10 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 Diabetic Peripheral Neuropathy Epidemiology in Spain (2017-2030)
  • Figure 12 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 Diabetic Peripheral Neuropathy Epidemiology in the United Kingdom (2017-2030)
  • Figure 14 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15 Diabetic Peripheral Neuropathy Epidemiology in Japan (2017-2030)
  • Figure 16 Diabetic Peripheral Neuropathy Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report